News
- Author:
- Heidi Splete
Publish date: March 28, 2024
Phase 3 randomized trial data supported FDA approval for linaclotide pediatric patients aged 6-17 years.
News
- Author:
- Heidi Splete
Publish date: March 19, 2024
Use of an Internet-based decision tool significantly increased knowledge of tubal sterilization as a permanent contraceptive option in a population...
News
- Author:
- Heidi Splete
Publish date: March 15, 2024
Data suggest physiologic differences as potential contributors to increased cesarean rates in patients with obesity.
News
- Author:
- Heidi Splete
Publish date: March 14, 2024
A snapshot assessment of metabolic syndrome is inadequate to show an association with cancer risk over time, the authors of new research say.
News
- Author:
- Heidi Splete
Publish date: March 11, 2024
Elevated trajectories of metabolic syndrome were associated with an elevated overall cancer risk.
News
- Author:
- Heidi Splete
Publish date: March 8, 2024
The exclusion of sulfites from most patch test series means that sulfite allergy diagnoses are often missed, despite the wide range of potential ex...
News
- Author:
- Heidi Splete
Publish date: March 8, 2024
Doctors are prepared to advocate for insurance coverage of the newly approved therapy on a case-by-case basis.
News
- Author:
- Heidi Splete
Publish date: March 7, 2024
Spironolactone, used off-label for several skin conditions in women, carries a warning about an increased tumor risk associated with high doses in ...
News
- Author:
- Heidi Splete
Publish date: March 6, 2024
Mortality risk in male patients showed different patterns over time than those seen in female patients.
News
- Author:
- Heidi Splete
Publish date: March 4, 2024
A comparison of screening tools for SpA in conditions that commonly co-occur with the disease revealed few screening tool options for patients with...
News
- Author:
- Heidi Splete
Publish date: February 29, 2024
Substance abuse, eating disorders, and sleep disorders were associated with fewer surgeries and greater risk of complications in cancer patients.
News
- Author:
- Heidi Splete
Publish date: February 28, 2024
If approved, dupilumab would be the only biologic option for COPD and the first new treatment option in approximately 10 years.
News
- Author:
- Heidi Splete
Publish date: February 28, 2024
The device is designed to provide reliable measures of oxygen saturation and pulse rate across all patient groups.
News
- Author:
- Heidi Splete
Publish date: February 27, 2024
Final safety results from 25 randomized clinical trials were consistent with previous reports at up to 6 years’ follow-up.
News
- Author:
- Heidi Splete
Publish date: February 26, 2024
Men had higher plasma triglyceride levels after hypoxemia, study finds, highlighting potential impact of OSA.
